Patients with early stage breast cancer are often treated with adjuvant systemic therapy (endocrine therapy, chemotherapy or agents against HER2) based on tumor characteristics such as HER2 status, tumor size and lymph node status. The gene discussed is ERBB2; the disease is breast cancer.